Caprion Biosciences and HistoGeneX merge to create the leader in immune monitoring and biomarker development.

Caprion Biosciences and HistoGeneX agreed to merge. Financial terms were not disclosed. The new partnership creates a global leader in immune monitoring, protein characterization, and tissue pathology solutions for immunotherapy and drug development. The combined business will provide a full suite of immune monitoring and biomarker development services, from preclinical through late stage clinical trials and companion diagnostics, to biopharmaceutical organizations globally.